Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Price:
40.16
CNY
-0.77%
Market Closed
Market Cap:
¥50.8B
Income Statement
Earnings Waterfall
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Income Statement
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Currency: CNY
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
1
|
2
|
2
|
3
|
4
|
6
|
8
|
9
|
8
|
8
|
7
|
7
|
8
|
7
|
7
|
6
|
5
|
8
|
9
|
0
|
0
|
|
| Revenue |
1 599
N/A
|
2 354
+47%
|
2 867
+22%
|
3 474
+21%
|
4 351
+25%
|
5 750
+32%
|
8 098
+41%
|
9 716
+20%
|
10 805
+11%
|
11 185
+4%
|
10 901
-3%
|
9 419
-14%
|
7 504
-20%
|
5 511
-27%
|
3 377
-39%
|
2 713
-20%
|
2 490
-8%
|
2 245
-10%
|
1 894
-16%
|
1 723
-9%
|
1 796
+4%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(323)
|
(471)
|
(497)
|
(570)
|
(647)
|
(848)
|
(1 051)
|
(1 211)
|
(1 270)
|
(1 191)
|
(1 138)
|
(984)
|
(899)
|
(993)
|
(777)
|
(776)
|
(772)
|
(860)
|
(713)
|
(750)
|
(928)
|
|
| Gross Profit |
1 277
N/A
|
1 883
+48%
|
2 370
+26%
|
2 904
+23%
|
3 704
+28%
|
4 903
+32%
|
7 047
+44%
|
8 506
+21%
|
9 535
+12%
|
9 994
+5%
|
9 763
-2%
|
8 435
-14%
|
6 605
-22%
|
4 518
-32%
|
2 599
-42%
|
1 937
-25%
|
1 718
-11%
|
1 386
-19%
|
1 181
-15%
|
973
-18%
|
868
-11%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(725)
|
(1 103)
|
(1 344)
|
(1 588)
|
(2 127)
|
(2 580)
|
(3 421)
|
(3 770)
|
(3 931)
|
(4 507)
|
(4 509)
|
(4 336)
|
(3 910)
|
(3 112)
|
(2 751)
|
(2 434)
|
(2 263)
|
(1 505)
|
(1 456)
|
(1 464)
|
(1 386)
|
|
| Selling, General & Administrative |
(551)
|
(808)
|
(1 008)
|
(1 229)
|
(1 552)
|
(1 940)
|
(2 778)
|
(3 122)
|
(3 453)
|
(3 585)
|
(3 508)
|
(3 196)
|
(2 541)
|
(1 869)
|
(1 203)
|
(980)
|
(903)
|
(691)
|
(731)
|
(768)
|
(783)
|
|
| Research & Development |
(193)
|
(300)
|
(348)
|
(389)
|
(575)
|
(658)
|
(710)
|
(711)
|
(608)
|
(1 040)
|
(1 211)
|
(1 329)
|
(1 532)
|
(1 102)
|
(1 187)
|
(1 214)
|
(1 111)
|
(783)
|
(818)
|
(683)
|
(605)
|
|
| Depreciation & Amortization |
0
|
(51)
|
0
|
0
|
0
|
(66)
|
0
|
0
|
0
|
(105)
|
0
|
0
|
0
|
(187)
|
0
|
0
|
0
|
(241)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
20
|
56
|
12
|
29
|
0
|
84
|
66
|
63
|
130
|
223
|
210
|
189
|
163
|
45
|
(362)
|
(240)
|
(249)
|
210
|
93
|
(14)
|
2
|
|
| Operating Income |
552
N/A
|
780
+41%
|
1 026
+32%
|
1 316
+28%
|
1 577
+20%
|
2 323
+47%
|
3 626
+56%
|
4 736
+31%
|
5 604
+18%
|
5 488
-2%
|
5 254
-4%
|
4 100
-22%
|
2 695
-34%
|
1 406
-48%
|
(152)
N/A
|
(497)
-227%
|
(545)
-10%
|
(119)
+78%
|
(275)
-131%
|
(491)
-79%
|
(519)
-6%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
10
|
(8)
|
5
|
(5)
|
2
|
7
|
(2)
|
29
|
67
|
108
|
144
|
175
|
197
|
218
|
248
|
235
|
205
|
205
|
177
|
165
|
157
|
|
| Non-Reccuring Items |
0
|
3
|
1
|
0
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
(222)
|
0
|
0
|
1
|
8
|
8
|
8
|
7
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Total Other Income |
(10)
|
(11)
|
(12)
|
(5)
|
(1)
|
(4)
|
(5)
|
(6)
|
(7)
|
(11)
|
(13)
|
(13)
|
(13)
|
(7)
|
(10)
|
(21)
|
(24)
|
(26)
|
(26)
|
(18)
|
(15)
|
|
| Pre-Tax Income |
552
N/A
|
765
+39%
|
1 019
+33%
|
1 307
+28%
|
1 579
+21%
|
2 324
+47%
|
3 619
+56%
|
4 758
+31%
|
5 664
+19%
|
5 583
-1%
|
5 385
-4%
|
4 262
-21%
|
2 879
-32%
|
1 393
-52%
|
86
-94%
|
(283)
N/A
|
(363)
-28%
|
67
N/A
|
(116)
N/A
|
(336)
-190%
|
(371)
-10%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(81)
|
(83)
|
(118)
|
(145)
|
(154)
|
(245)
|
(443)
|
(628)
|
(759)
|
(719)
|
(656)
|
(468)
|
(244)
|
(147)
|
38
|
84
|
68
|
42
|
41
|
36
|
35
|
|
| Income from Continuing Operations |
471
|
682
|
901
|
1 163
|
1 425
|
2 079
|
3 176
|
4 130
|
4 905
|
4 863
|
4 729
|
3 793
|
2 636
|
1 247
|
124
|
(199)
|
(295)
|
109
|
(75)
|
(300)
|
(335)
|
|
| Income to Minority Interest |
(4)
|
(5)
|
(6)
|
(8)
|
(26)
|
(58)
|
(113)
|
(137)
|
(128)
|
(128)
|
(79)
|
(48)
|
(35)
|
1
|
5
|
5
|
1
|
(3)
|
3
|
2
|
1
|
|
| Net Income (Common) |
467
N/A
|
677
+45%
|
896
+32%
|
1 155
+29%
|
1 398
+21%
|
2 021
+45%
|
3 063
+52%
|
3 993
+30%
|
4 777
+20%
|
4 736
-1%
|
4 650
-2%
|
3 745
-19%
|
2 600
-31%
|
1 248
-52%
|
128
-90%
|
(194)
N/A
|
(294)
-51%
|
106
N/A
|
(72)
N/A
|
(298)
-313%
|
(334)
-12%
|
|
| EPS (Diluted) |
0.8
N/A
|
1.16
+45%
|
1.47
+27%
|
1.31
-11%
|
1.59
+21%
|
1.64
+3%
|
3.48
+112%
|
4.54
+30%
|
3.77
-17%
|
3.79
+1%
|
3.67
-3%
|
2.96
-19%
|
2.07
-30%
|
0.99
-52%
|
0.09
-91%
|
-0.16
N/A
|
-0.24
-50%
|
0.08
N/A
|
-0.04
N/A
|
-0.21
-425%
|
-0.3
-43%
|
|
Switch to:
Switch to:
See Also
Discover More
